Improved treatments can minimize the adverse effects of specific drug therapies.
改善过的治疗方法可以减少某些药物治疗的不利作用。
CONCLUSIONS:Panshengan is a cell cycle-specific drug which can arrest the cells at G1/G0 phase.
结论:盼生安是周期特异性药物,通过将细胞阻滞于G1/G0 期而抑制其增殖。
Tongbiantong capsule, an oral preparation for colon site-specific drug delivery, is anew remedy for constipation.
新药通便通胶囊是一种治疗便秘的口服结肠靶向给药制剂。
Fructose -1, 6-diphosphate (FDP) is a new kind of specific drug on a cell molecular level used to cure cardiovascular disease.
果糖—1,6—二磷酸(FDP)是一种新型治疗心血管疾病的细胞分子水平特效药。
Polysaccharides are used as colon-specific drug delivery carriers because they can be degraded by enzymes produced by colon bacteria.
多糖能被结肠内的菌群降解,而被用作结肠靶向给药的载体。
OBJECTIVE To prepare the 5 aminosalicylic acid (5 ASA) enteric time controlled released tablets with site specific drug delivery in colon.
目的制备5氨基水杨酸(5ASA)肠溶包衣片,使药物在结肠释放。
To establish a preparation technique of Metronidazole- loaded colon specific drug delivery systems by centrifuge coating granulation method.
初步确立离心包衣造粒技术制备甲硝唑结肠靶向制剂的方法。
Objective: To introduce the progress of research on the pharmaceutical approaches to oral colon-specific drug delivery system in recent years.
目的:介绍近年来口服结肠定位给药方法药剂学方面的研究进展。
In case of extravasation, the correct treatment according to the specific drug should be given to reduce the inflammation and tissue necrosis.
应以预防为主,一旦发生药物外渗,根据不同外渗药物,立即采取相应处理,减少炎症和组织坏死。
Background and Objective: OCDDS (Oral Colon-specific drug delivery system) is a kind of drug target delivery systems, which can deliver drug at colon.
背景与目的:口服结肠靶向给药系统(OCDDS)是一种将药物定位释放于结肠的靶向制剂。
This article provides a review of starch structure, digestibility and its influencing factors and the application outlook of starch-based carrier for oral colon-specific drug delivery system.
综述了淀粉的结构、消化特性、影响淀粉消化特性的因素及其在口服结肠靶向药物控释载体中的应用前景。
Objective: To study of Metronidazole Colon Site-specific Drug Delivery Capsule.
前言:目的:研制甲硝唑结肠定位胶囊。
Specific drug–polymer interactions are engineered by optimizing the lactide to glycolide ratio and including specific polymer end groups.
通过优化丙交酯与乙交酯比例及加入特殊的聚合物末端基来获得特殊的药物-聚合物间相互作用。
Specific drug–polymer interactions are engineered by optimizing the lactide to glycolide ratio (L:G ratio) and including specific polymer end groups.
通过优化丙交酯与乙交酯比例(L:G比)及加入特殊的聚合物末端基来获得特殊的药物-聚合物间相互作用。
Specific drug–polymer interactions are engineered by optimizing the lactide to glycolide ratio (L:G ratio) and including specific polymer end groups.
通过优化丙交酯与乙交酯比例(L:G比)及加入特殊的聚合物末端基来获得特殊的药物-聚合物间相互作用。
应用推荐